Real-life experience of ceritinib in crizotinib-pretreated ALK(+) advanced non-small cell lung cancer patients

Here we report our experience of ceritinib in crizotinib-pretreated patients with anaplastic lymphoma kinase (ALK) positive (ALK(+)) non-small cell lung cancer (NSCLC) in a French temporary authorisation for use (TAU) study. The French TAU study included crizotinib-pretreated patients with advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Cadranel, Jacques, Cortot, Alexis B., Lena, Hervé, Mennecier, Bertrand, Do, Pascal, Dansin, Eric, Mazieres, Julien, Chouaid, Christos, Perol, Maurice, Barlesi, Fabrice, Robinet, Gilles, Friard, Sylvie, Thiberville, Luc, Audigier-Valette, Clarisse, Vergnenegre, Alain, Westeel, Virginie, Slimane, Khemaies, Buturuga, Alexandru, Moro-Sibilot, Denis, Besse, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810621/
https://www.ncbi.nlm.nih.gov/pubmed/29450203
http://dx.doi.org/10.1183/23120541.00058-2017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810621/
https://www.ncbi.nlm.nih.gov/pubmed/29450203
http://dx.doi.org/10.1183/23120541.00058-2017

Ejemplares similares